FiercePharma7h
Eli Lilly's Zepbound defeats Novo Nordisk's Wegovy in head-to-head weight loss trial
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...
Lightning Round: I prefer Eli Lilly over Regeneron
Parts of New York state faced up to five feet of snow over the last few days and more is coming across the Great Lakes region ...
STAT1d
Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves
Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.
Eli Lilly & Co. stock outperforms competitors on strong trading day
Shares of Eli Lilly & Co. LLY advanced 1.69% to $813.33 Tuesday, on what proved to be an all-around mixed trading session for ...
Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...
Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...